Abstract
Most data on osteosarcoma is derived from pediatric studies. Although the majority of adult patients with osteosarcoma are young adults, who might be treated in a similar fashion, experience derived from a slightly older population is helpful in directing therapy. We treated a series of 123 patients with osteosarcoma of the extremities with adriamycin and cisplatin as induction therapy. Adriamycin was infused intravenously at 90 mg/m2 over 96 h. Cisplatin was infused intra-arterially at 120–160 mg/m2 over 2–24 h. Sequential addition of methotrexate and methotrexate plus ifosfamide in subsequent cohorts improved the continuous relapse-free survival of poor responders such that overall survival improvement was noted in the group where therapy was modified by adding both agents to those with <90% tumor necrosis. Patients with chondroblastic osteosarcoma with poor necrosis had a trend towards improved continuous relapse-free survival compared with other patients with conventional osteosarcoma. Histologic variants of osteosarcoma except telangiectatic osteosarcoma had a worse prognosis than those with conventional osteosarcoma. The variants, especially dedifferentiated parosteal osteosarcoma and dedifferentiated well-differentiated intraosseous osteosarcoma are more common in adults than children, accounting for some of the inferior prognosis in adults. Older patients obviously cannot tolerate the doses of therapy given to children and young adults, again decreasing the chances of successful treatment. Patients with secondary osteosarcoma are often much older as are many with osteosarcomas of the pelvis and jaw. These tumors tend to be less responsive. An attempt to intensify therapy in poor-prognosis patients with a three-drug regimen of adriamycin, cisplatin, and ifosfamide with peripheral stem cell support was unsuccessful at prolonging relapse-free survival, and we no longer use that approach.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benjamin RS, Murray JA, Wallace S, et al. Intra-arterial preoperative chemotherapy for osteosarcoma – a judicious approach to limb salvage. Cancer Bull. 1984;36:32-36.
Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Sem Diag Path. 1987;4:212-236.
Benjamin RS. Regional chemotherapy for osteosarcoma. Semin Onocol. 1989;16:323-327.
Benjamin RS, Chawla SP, Carrasco CH, et al. Primary chemotherapy for osteosarcoma with systemic adriamycin and intra-arterial cisplatin. Cancer Bull. 1990;42:314-317.
Benjamin RS, Chawla SP, Carrasco CH, et al. Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum. Ann Oncol. 1992;3(Suppl 2):S3-S6.
Benjamin RS, Patel SR, Armen T, et al. Primary chemotherapy of osteosarcoma of the extremities – long-term follow-up. Am Soc Clin Oncol. 1993;12:470.
Benjamin RS, Patel SR, Armen T, et al. The value of ifosfamide in postoperative neoadjuvant chemotherapy of osteosarcoma. Am Soc Clin Oncol. 1995;14:516.
Benjamin RS. Thirty years of progress in the chemotherapy of soft-tissue sarcomas and osteosarcoma in adults and prospects for the future. J Jpn Ortho Assoc. 1997;71:S1127.
Patel SR, Benjamin RS. Current status of chemotherapy for bone sarcomas. Indian J Med Ped Onc. 1997;18:5-8.
Mosende C, Gutierrez M, Caparros B, Rosen G. Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer. 1977;40:2779-2786.
Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-1230.
Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72:3227-3238.
Chawla SP, Benjamin RS. Effectiveness of chemotherapy in the management of metastatic telangiectatic osteosarcoma. Am J Clin Oncol. 1988;11:177-180.
Ayala AG, Ro JY, Raymond AK, et al. Small cell osteosarcoma: a clinicopathologic study of 27 cases. Cancer. 1989;64:2162-2173.
Sheth DS, Yak AW, Raymond AK, et al. Conventional and dedifferentiated parosteal osteosarcoma: diagnosis, treatment and outcome. Cancer. 1996;78:2136-2145.
Patel SR, Papadopolous N, Raymond AK, et al. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer. 2004;101:156-163.
Longhi A, Errani C, Gonzales-Arabio D et al: Osteosarcoma in patients older than 65 years. J Clin Oncol. 2008; 28: 5368-73.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Benjamin, R.S., Patel, S.R. (2009). Pediatric and Adult Osteosarcoma: Comparisons and Contrasts in Presentation and Therapy. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_19
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0284-9_19
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0283-2
Online ISBN: 978-1-4419-0284-9
eBook Packages: MedicineMedicine (R0)